<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2548">
  <stage>Registered</stage>
  <submitdate>18/09/2009</submitdate>
  <approvaldate>18/09/2009</approvaldate>
  <nctid>NCT01004081</nctid>
  <trial_identification>
    <studytitle>Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding</studytitle>
    <scientifictitle>Phase 2a, Open-Label, Randomized, Noncomparative Study of BIIB021 in Combination With Exemestane in Women With Hormone Receptor-Positive, Advanced Metastatic Breast Cancer Who Have Progressed on a Nonsteroidal Aromatase Inhibitor</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>120BC201</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Breast Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Breast</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - BIIB021
Treatment: drugs - BIIB021
Treatment: drugs - exemestane (Aromasin)

Experimental: BIIB021 BID + exemestane - BIIB021 100 mg BID + exemestane 25 mg QD

Experimental: BIIB021 TIW + exemestane - BIIB021 450 mg TIW + exemestane 25 mg QD


Treatment: drugs: BIIB021
BID orally for 28 days

Treatment: drugs: BIIB021
TIW orally for 28 days

Treatment: drugs: exemestane (Aromasin)
Daily in tablet form for 28 days

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The primary objective of this study is to assess the efficacy of 2 dosing regimens of BIIB021 in combination with exemestane in women whose HR+ breast cancer had progressed following treatment with a nonsteroidal AI.</outcome>
      <timepoint>As specified in protocol</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>The secondary objective of this study is to evaluate the safety and tolerability of BIIB021 in combination with exemestane in this study population.</outcome>
      <timepoint>As specified in protocol</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Age 18 years of age

          -  Must have histologically or cytologically confirmed estrogen receptor- positive or
             progesterone receptor-positive, incurable, locally advanced, or metastatic breast
             cancer.

          -  Must have disease progression during treatment with a nonsteroidal AI for locally
             advanced or metastatic disease, or relapse during treatment or within 12 months of
             discontinuation of treatment in the adjuvant setting.

          -  Must be a postmenopausal female.

          -  Must have measurable or evaluable disease.

               -  Measurable disease is defined as &gt;=1 lesion with a diameter of &gt;=10 mm

               -  Evaluable disease is defined as bone lesions evaluable by plain X ray, CT scan,
                  or MRI. Lesions identified only by radionuclide bone scan are not allowed.

          -  One prior chemotherapy regimen for advanced mBC is allowed.

          -  Prior radiotherapy is allowed.

          -  Must be able to swallow and retain oral medication.

          -  ECOG performance status of &lt;=2

          -  Required laboratory values

               -  Plasma cortisol and adrenocorticotropic hormone (ACTH) levels that are not
                  suggestive of adrenal insufficiency unless on replacement therapy for known
                  adrenal insufficiency.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Female</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  HER2 overexpressing tumor.

          -  History of central nervous system (CNS) metastasis.

          -  Previous treatment with exemestane or treatment with an Hsp90 inhibitor.

          -  Use of proton pump inhibitors.

          -  Known history of or positive test result for hepatitis B or C or HIV.

          -  History of gastrectomy or major surgery to small intestine.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/11/2009</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>54</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/10/2011</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,TAS,VIC</recruitmentstate>
    <hospital>Research Site - Waratah</hospital>
    <hospital>Research Site - Wollongong</hospital>
    <hospital>Research Site - Herston</hospital>
    <hospital>Research Site - Redcliffe</hospital>
    <hospital>Research Site - Hobart</hospital>
    <hospital>Research Site - Geelong</hospital>
    <postcode> - Waratah</postcode>
    <postcode> - Wollongong</postcode>
    <postcode> - Herston</postcode>
    <postcode> - Redcliffe</postcode>
    <postcode> - Hobart</postcode>
    <postcode> - Geelong</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alabama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Dakota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Brasschaat</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Edegem</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Kortrijk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Liege</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Mons</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Kuzmolovskiy</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Moscow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Ryazan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>St. Petersburg</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Biogen</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to assess the efficacy, safety and tolerability of 2 dosing
      regimens of BIIB021 in combination with exemestane in women whose HR+ breast cancer had
      progressed following treatment with a nonsteroidal aromatase inhibitor (AI).</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01004081</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Medical Director</name>
      <address>Biogen</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>